Axicabtagene Ciloleucel (Yescarta)
CD19-directed CAR-T cell therapy for relapsed or refractory large B-cell lymphoma and follicular lymphoma.
What is Axicabtagene Ciloleucel?
What it targets
CD19, a protein expressed on most B-cell lymphoma cells — the patient's own T cells are engineered to recognise and attack CD19-positive cells.
Who it may help
Adults with relapsed or refractory large B-cell lymphoma, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, or follicular lymphoma after prior lines of therapy.
Why testing matters
Confirmation of CD19-positive disease, leukapheresis to collect T cells, and organ function tests are needed before manufacturing and infusion can begin.
Which lymphomas can axicabtagene ciloleucel treat?
Yescarta is approved for selected adults with the following B-cell lymphoma subtypes in defined relapsed or refractory settings.
| Diffuse large B-cell lymphoma (DLBCL) | Relapsed or refractory DLBCL in adults after prior chemoimmunotherapy, including early relapse after first-line treatment. |
| Large B-cell lymphoma | Refractory disease or relapse after first-line therapy; FDA approval includes early relapse within 12 months of first-line chemoimmunotherapy. |
| Primary mediastinal large B-cell lymphoma (PMBCL) | Later-line use in selected adults with relapsed or refractory PMBCL per EMA approval. |
| High-grade B-cell lymphoma | Selected relapsed or refractory high-grade B-cell lymphoma; included in EMA-approved indications. |
| DLBCL arising from follicular lymphoma | Included within large B-cell lymphoma indications; eligible when other criteria are met. |
| Follicular lymphoma (Grade 1–3a) | Adults with relapsed or refractory follicular lymphoma who have received two or more prior lines of systemic therapy per FDA and EMA approvals. |
Who may be eligible for Yescarta?
Eligibility is determined by a CAR-T specialist and depends on lymphoma type, prior treatment, organ function, and certified centre access.
- Confirmed CD19-positive B-cell lymphoma on recent biopsy.
- Large B-cell lymphoma refractory to, or relapsed within 12 months of, first-line chemoimmunotherapy.
- Follicular lymphoma relapsed or refractory after two or more prior lines of systemic therapy.
- Adequate cardiac, hepatic, renal, and pulmonary function to tolerate CAR-T treatment.
- No active uncontrolled infection or active inflammatory disorder.
- Disease that can be managed safely during the CAR-T manufacturing period.
- No prior allogenic stem cell transplant within 6 months or active graft-versus-host disease.
- Ability to remain near a certified CAR-T centre for at least four weeks after infusion.
- No primary central nervous system lymphoma — this indication is excluded per FDA labelling.
- A treating specialist who judges expected benefit to outweigh individual risks.
How does axicabtagene ciloleucel work?
- T-cell collection (leukapheresis)
- Genetic engineering
- Cell expansion and quality testing
- Bridging therapy (if needed)
- Lymphodepleting chemotherapy
- CAR-T infusion
- Immune response and monitoring
Tests needed before axicabtagene ciloleucel treatment
A comprehensive workup is required before CAR-T eligibility is confirmed and leukapheresis can be scheduled.
| Lymphoma biopsy and pathology | Confirms lymphoma subtype and CD19 expression by immunohistochemistry or flow cytometry. |
| PET-CT or CT staging scan | Defines disease extent and identifies sites that may need bridging therapy. |
| Complete blood count (CBC) | Assesses baseline blood counts; guides eligibility and timing decisions. |
| Liver and kidney function tests | Required to confirm organ fitness for lymphodepleting chemotherapy and CAR-T infusion. |
| Cardiac evaluation | ECG and echocardiogram to ensure the heart can tolerate the procedure and potential CRS. |
| Viral serology | Hepatitis B, hepatitis C, HIV, and other infectious screening per centre protocol. |
| Bone marrow biopsy | Performed when clinically indicated to assess marrow involvement. |
| Neurological baseline assessment | Documents baseline cognitive and neurological status before infusion. |
| Coagulation profile | Checks clotting function as DIC can complicate severe CRS. |
| Pregnancy test | Required for patients of childbearing potential before lymphodepleting chemotherapy. |
How is axicabtagene ciloleucel given?
Axicabtagene ciloleucel is administered as a single intravenous infusion at a certified CAR-T treatment centre. It is not a routine outpatient injection or a repeating chemotherapy cycle.
| Dose | Single infusion of 2 × 10⁶ CAR-positive viable T cells per kg body weight, up to a maximum of 2 × 10⁸ cells. |
| Infusion route | Intravenous infusion only; must be given at a certified CAR-T centre with trained staff and emergency support. |
| Lymphodepleting chemotherapy | Fludarabine and cyclophosphamide given on days –5 to –3 before infusion to prepare the immune environment. |
| Infusion timing | Yescarta is infused on day 0, typically about 30 to 60 minutes per infusion bag. |
| Post-infusion monitoring period | Patients must remain near the CAR-T centre for at least four weeks to monitor for CRS, neurologic toxicity, and infection. |
| Driving restriction | Patients are advised not to drive, operate heavy machinery, or perform high-risk activities for at least eight weeks after infusion due to potential neurologic effects. |
| Duration | Axicabtagene ciloleucel is a one-time cell infusion; it is not a repeating treatment cycle. |
Clinical evidence and potential benefits
Axicabtagene ciloleucel has demonstrated significant activity in heavily pre-treated aggressive B-cell lymphomas in pivotal and real-world studies.
| ZUMA-1 trial — large B-cell lymphoma | The pivotal ZUMA-1 study demonstrated durable complete responses in a substantial proportion of patients with refractory large B-cell lymphoma, with a meaningful percentage maintaining remission at long-term follow-up. |
| ZUMA-7 trial — second-line DLBCL | In ZUMA-7, axicabtagene ciloleucel significantly improved event-free survival versus standard second-line chemoimmunotherapy in patients with early-relapsed or refractory large B-cell lymphoma. |
| ZUMA-5 trial — follicular lymphoma | ZUMA-5 demonstrated high overall and complete response rates in patients with relapsed or refractory follicular lymphoma after two or more prior lines of therapy, with durable remissions in a meaningful proportion. |
| One-time treatment approach | CAR-T therapy is a single infusion — not a repeating cycle — which may offer a fundamentally different approach for patients who have exhausted standard options. |
| Potential for durable remission | A subset of patients achieve long-term disease-free remission after axicabtagene ciloleucel, a meaningful outcome in aggressive lymphoma settings where prior therapy has failed. |
| Personalised immune therapy | Manufactured from the patient's own T cells, Yescarta represents a highly individualised treatment designed to harness the patient's own immune system. |
Individual responses vary considerably. Not all patients achieve remission and some may relapse. These outcomes represent published clinical study data and are not guaranteed for any individual patient.
Side effects of axicabtagene ciloleucel
Axicabtagene ciloleucel can cause serious, potentially life-threatening side effects. The prescribing information includes boxed warnings for cytokine release syndrome, neurologic toxicities, and secondary haematological malignancies. All patients must be treated at a certified centre.
| Cytokine release syndrome (CRS) | Very common; ranges from fever and fatigue to severe hypotension and hypoxia. Managed with tocilizumab and/or corticosteroids at a certified centre. |
| Neurologic toxicities (ICANS) | Immune effector cell-associated neurotoxicity syndrome — may include confusion, difficulty speaking, tremor, or seizures. Requires close monitoring and specialist management. |
| Fever | Occurs in the majority of patients, often as the first sign of CRS. Always report fever promptly after CAR-T infusion. |
| Low blood pressure (hypotension) | Common with CRS; may require IV fluids, vasopressors, and ICU-level support in severe cases. |
| Low oxygen levels (hypoxia) | Occurs with moderate-to-severe CRS; may require supplemental oxygen or mechanical ventilation. |
| Fatigue | Very common in the weeks following infusion; typically improves as the immune response settles. |
| Low white blood cells (neutropenia) | Expected following lymphodepleting chemotherapy; increases infection risk and requires growth factor support in many patients. |
| Anaemia | Common after lymphodepleting chemotherapy and CAR-T infusion; may require transfusion support. |
| Low platelets (thrombocytopenia) | Occurs frequently; risk of bleeding if severe. Platelet transfusions may be given. |
| Infection risk | Substantially increased due to lymphodepleting chemotherapy, hypogammaglobulinaemia, and immune reconstitution delay. Prophylaxis and close monitoring are standard. |
| Low immunoglobulin levels | B-cell aplasia after CAR-T therapy can persist for months; immunoglobulin replacement may be required. |
| Secondary haematological malignancies | A boxed warning identifies the risk of T-cell malignancies, including CAR-T cell lymphoma. Report new or worsening symptoms promptly. |
Seek emergency medical attention immediately if you develop:
- Fever at any time after CAR-T infusion — this is always urgent.
- Breathing difficulty, low oxygen levels, or rapid heartbeat.
- Confusion, extreme drowsiness, or difficulty speaking or writing.
- Seizures or uncontrolled shaking of limbs.
- Severe low blood pressure, dizziness, or fainting.
- Signs of active infection including rigors, chills, or new localised pain.
- Unusual or unexpected bleeding or bruising.
Safety precautions and important warnings
Tell your CAR-T team about all medical conditions, prior therapies, medications, supplements, and herbal products before starting the evaluation process.
- Active or recent infections — including hepatitis B, hepatitis C, HIV, tuberculosis, or fungal infections — must be disclosed and managed before CAR-T therapy can proceed.
- Neurological history — prior seizures, stroke, neuropathy, encephalopathy, or cognitive impairment should be documented and reviewed by the CAR-T team.
- Prior CD19-directed therapy — previous treatment with CD19 antibodies or other CAR-T products may affect CD19 expression and eligibility.
- Prior allogeneic stem cell transplant — recent transplant or active graft-versus-host disease is a contraindication or requires careful evaluation.
- Autoimmune disease — active autoimmune conditions may increase the risk of severe immune-related toxicity.
- Pregnancy and breastfeeding — axicabtagene ciloleucel should not be given during pregnancy; effective contraception must be discussed with the treating team.
- Corticosteroids and immunosuppressants — routine use may impair CAR-T cell expansion; the team must review and approve any ongoing use.
- Live vaccines — must not be administered to immunocompromised patients; discuss timing with the CAR-T team before and after therapy.
- Driving and machinery — patients must not drive or operate heavy machinery for at least eight weeks after infusion due to neurologic risk.
Axicabtagene ciloleucel combination and sequencing strategies
Axicabtagene ciloleucel is generally used as a standalone infusion after lymphodepleting chemotherapy. The broader treatment pathway may involve bridging therapy and carefully planned sequencing with other agents.
| Bridging therapy before CAR-T | Selected patients receive short-course chemotherapy, steroid-based regimens, or radiotherapy to control lymphoma growth during the manufacturing period. |
| Lymphodepleting chemotherapy | Fludarabine and cyclophosphamide are given as a fixed conditioning regimen immediately before CAR-T infusion to improve CAR-T cell engraftment. |
| Radiotherapy for urgent disease control | Palliative or consolidative radiation may be used for bulky or compressing disease sites before or alongside CAR-T planning. |
| Post-CAR-T options if relapse occurs | Bispecific antibodies (epcoritamab, glofitamab, mosunetuzumab), antibody-drug conjugates (loncastuximab tesirine), and clinical trial therapies are options following CAR-T failure. |
| Sequencing with bispecific antibodies | Optimal sequencing of CAR-T therapy relative to bispecific antibodies is an active clinical question; a lymphoma specialist should guide the choice based on CD19 status and disease behaviour. |
| Stem cell transplant and CAR-T | CAR-T therapy may be considered for patients who failed or are ineligible for autologous stem cell transplant; transplant after CAR-T is rarely performed but may be considered in selected cases. |
If axicabtagene ciloleucel stops working
Primary or secondary non-response and relapse after CAR-T therapy require reassessment of lymphoma biology and a review of all available treatment options.
| CD19 antigen loss | The most common mechanism of resistance; lymphoma cells downregulate or lose CD19 expression, rendering CAR-T cells unable to recognise them. Confirmed by repeat biopsy. |
| CAR-T cell exhaustion or poor expansion | Inadequate CAR-T cell proliferation or early T-cell exhaustion can prevent a durable response, particularly in patients with high tumour burden or poor T-cell fitness. |
| Tumour microenvironment suppression | An immunosuppressive tumour microenvironment can inhibit CAR-T cell function. Research into overcoming this through combination strategies is ongoing. |
| Next-line options after CAR-T failure | Bispecific antibodies such as epcoritamab or glofitamab, loncastuximab tesirine, polatuzumab vedotin-based regimens, salvage chemotherapy, allogeneic transplant, or clinical trial enrolment. |
| Second CAR-T or alternative CD19 products | A second CAR-T infusion after Yescarta is investigational. Alternative targets such as CD22 or CD20 are being explored in trial settings for CD19-negative relapse. |
Cost of axicabtagene ciloleucel by country
CAR-T therapy is among the most expensive cancer treatments globally because it involves bespoke cell manufacturing, specialised hospital infrastructure, and intensive post-infusion care.
| USA | The list price for Yescarta is approximately USD 373,000 for the drug alone. Total treatment costs including lymphodepletion, hospitalisation, toxicity management, and monitoring can substantially exceed this. Gilead offers a patient assistance programme; commercial and government insurance coverage varies by plan and indication. |
| UK / Europe | NICE and some European health technology agencies have approved Yescarta for defined indications under managed access or reimbursement agreements. Self-pay costs in Europe mirror the USA range. Check local national health authority coverage before planning. |
| India | Yescarta is not commercially approved in India as of 2026. Indian patients seeking access must travel to an approved centre internationally. Total costs including travel, treatment, and extended stay abroad vary considerably. CancerFax can assist with pathway and cost guidance. |
| China | Domestic CD19 CAR-T products (relmacabtagene autoleucel, axicabtagene ciloleucel-equivalent) are approved and may offer more accessible pricing compared to Western markets. Costs vary by hospital and whether national reimbursement is available. |
| Singapore / South Korea / UAE | Approved or accessible at selected certified cancer centres; costs are broadly comparable to USA or European pricing. Insurance coverage and self-pay options vary significantly by country and payer. |
Global availability of axicabtagene ciloleucel
Yescarta is FDA and EMA approved, but practical access depends on certified CAR-T centre availability, manufacturing logistics, and national reimbursement policies.
USA
FDA-approved for large B-cell lymphoma and follicular lymphoma. Available at certified CAR-T centres nationwide. Patient assistance programmes are available through Gilead. Coverage through Medicare, Medicaid, and commercial insurance varies.
UK
EMA and MHRA approved. Available at NHSE-designated CAR-T centres under managed access arrangements. Patients outside England should check relevant national health authority coverage.
Europe (EMA countries)
EMA-approved across the EU and EEA. Access depends on national HTA decisions, reimbursement agreements, and availability of certified centres in each country. Some countries have full coverage; others require case-by-case approval.
China
Domestic CAR-T products targeting CD19 are approved by the NMPA. Multiple certified CAR-T centres operate in major cities. Pricing may be more accessible than Western markets. Clinical trials for CD19 CAR-T are also active.
India
Yescarta is not approved in India as of 2026. Access is via international referral or through investigational CAR-T trials. Some Indian centres are developing indigenous CD19 CAR-T programmes. CancerFax can advise on referral pathways.
Singapore / South Korea
Available at selected certified oncology centres. Both countries have regulatory approvals or named patient access pathways. These are common referral destinations for CAR-T access from South and Southeast Asia.
Axicabtagene ciloleucel in current clinical trials
Active research continues to explore axicabtagene ciloleucel in earlier lines of therapy, new combinations, and against the challenge of CAR-T relapse.
| Earlier-line and first-line aggressive DLBCL | Trials are investigating whether moving CAR-T therapy to first-line or high-risk settings can improve outcomes compared to standard chemoimmunotherapy in newly diagnosed high-risk DLBCL. |
| Combination with checkpoint inhibitors | Studies are exploring axicabtagene ciloleucel combined with PD-1/PD-L1 inhibitors to overcome tumour immune suppression and enhance CAR-T cell persistence and activity. |
| Overcoming CAR-T resistance | Trials are testing strategies for patients who relapse after CAR-T, including CD22-directed CAR-T, bispecific CAR-T constructs, and CD19/CD22 dual-targeting products for CD19-negative relapse. |
| CAR-T after bispecific antibody therapy | As bispecific antibodies become earlier-line options, optimal sequencing with CAR-T therapy is under active investigation, including whether prior bispecific exposure affects CD19 expression and CAR-T outcomes. |
| Follicular lymphoma — earlier-line use | Trials are evaluating axicabtagene ciloleucel in follicular lymphoma settings earlier than currently approved, to assess whether CAR-T can replace or delay conventional therapies in this indolent but recurring disease. |
Your treatment journey with axicabtagene ciloleucel
Lymphoma diagnosis and subtype confirmation
CAR-T specialist referral and eligibility review
Pre-treatment workup and staging
T-cell collection (leukapheresis)
Bridging therapy during manufacturing
Lymphodepleting chemotherapy
Yescarta infusion
Post-infusion monitoring (first 4 weeks)
Response assessment
Long-term follow-up
Questions to ask your oncologist about axicabtagene ciloleucel
- Is my lymphoma CD19-positive and eligible for Yescarta?
- Is my disease growing too quickly to wait for CAR-T manufacturing?
- What are the risks of cytokine release syndrome in my specific case?
- How long will I need to stay near the CAR-T centre after infusion?
- What happens to my immune system after CAR-T therapy?
- What is the estimated total cost and what financial support is available?
- Are there alternative CAR-T products or clinical trials I should consider?
- What are my options if Yescarta does not work or if the lymphoma comes back?
How CancerFax supports axicabtagene ciloleucel patients
CancerFax helps lymphoma patients and families navigate CAR-T eligibility, access, and care coordination across India, China, and international centres.
| Medical report review | Upload your biopsy, CD19 results, PET-CT reports, and treatment history — our oncology team will review eligibility and explain your CAR-T options. |
| Specialist connection | We connect patients with haematologists and CAR-T specialists at certified centres in China, Singapore, South Korea, USA, and Europe. |
| India access guidance | For Indian patients where Yescarta is unavailable domestically, we evaluate international CAR-T access, local clinical trials, and emerging domestic CAR-T programmes. |
| China CAR-T referral | China offers approved domestic CD19 CAR-T products at certified centres. CancerFax can evaluate suitability and facilitate referrals including translation, logistics, and coordination. |
| Second opinion on CAR-T eligibility | If you have been told you may or may not be suitable for CAR-T, we arrange a second opinion with a lymphoma and cell therapy specialist to ensure the most informed decision. |
| Cost and logistics planning | We help patients understand total cost, financial assistance options, travel requirements, and accommodation planning near CAR-T centres internationally. |
Frequently asked questions about axicabtagene ciloleucel
Common questions from patients, caregivers, and families
Axicabtagene ciloleucel is a CAR-T cell therapy, not a chemotherapy drug. It uses the patient's own T cells, which are collected, genetically engineered to recognise the CD19 protein on lymphoma cells, and then infused back into the body. Unlike chemotherapy, which attacks rapidly dividing cells broadly, CAR-T therapy is a targeted, living treatment that can persist and continue working in the body over time.
Yes. CD19 expression is a prerequisite for axicabtagene ciloleucel because the CAR-T cells are specifically engineered to target CD19. Your oncologist will confirm CD19 status from a recent biopsy using immunohistochemistry or flow cytometry before the treatment process begins. CD19 loss after prior CD19-directed therapy may affect eligibility.
The full process typically takes four to six weeks from T-cell collection to infusion. After leukapheresis, the cells are shipped to a manufacturing facility where they are engineered and expanded, which usually takes two to four weeks. During this waiting period, some patients receive bridging therapy to control the lymphoma. Hospital monitoring after infusion can extend for several additional weeks.
Cytokine release syndrome, or CRS, occurs when the infused CAR-T cells become very active and release large amounts of inflammatory proteins called cytokines. It can cause fever, low blood pressure, low oxygen levels, and rapid heartbeat, and in severe cases requires ICU-level care. Most cases are manageable with tocilizumab and corticosteroids at a certified CAR-T centre. The Yescarta prescribing information includes a boxed warning for CRS because it can be life-threatening if not promptly treated.
The infusion itself may be initiated in a hospital or qualified outpatient setting, but patients are required to remain near the certified CAR-T centre for at least four weeks after infusion because serious side effects such as cytokine release syndrome and neurologic toxicity can occur early and require rapid intervention. Patients should not drive or operate heavy machinery during this period.
As of 2026, axicabtagene ciloleucel (Yescarta) is not commercially approved in India. Indian patients seeking CAR-T therapy may access it through international referral to approved centres in countries such as the USA, UK, Singapore, or South Korea, through emerging local CD19 CAR-T products or clinical trials in India, or via approved access pathways in China where domestic CAR-T therapies are available. CancerFax can help evaluate which pathway is most appropriate for each patient.
If lymphoma progresses after axicabtagene ciloleucel, a repeat biopsy is usually recommended to confirm relapse and reassess CD19 expression, since CD19 loss can occur. Your oncologist will review options including bispecific antibodies such as epcoritamab or glofitamab, antibody-drug conjugates, salvage chemotherapy, autologous or allogeneic stem cell transplant, or clinical trial enrolment. A specialist second opinion is often helpful in this setting.
Axicabtagene ciloleucel should not be used during pregnancy. The lymphodepleting chemotherapy given before CAR-T infusion is harmful to a developing foetus, and the safety of CAR-T therapy itself in pregnancy has not been established. Patients who are pregnant or planning to become pregnant must discuss this with their oncologist before any CAR-T evaluation. Effective contraception is typically advised for a defined period after treatment.